Tag: molecular biomarkers
MEDITE Cancer Diagnostics Reports a Profitable Q3 and Nine Month 2015 Results (OTC:MDIT)
NEWS: MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT / OTCMKTS:MDIT) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its third quarter and nine month 2015 results.
MEDITE Cancer Diagnostics, Inc. (OTC:MDIT) Reports Q2 and Six Month 2015 Results
ORLANDO, Fla. /eNewsChannels/ -- NEWS: MEDITE Cancer Diagnostics, Inc. ('Company,' OTCQB symbol: MDIT / OTCBB:MDIT / OTCMKTS:MDIT), specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces second quarter and six month 2015 results.
Medical Technology Firm, MEDITE Cancer Diagnostics, Engages New Auditing-CPA Provider
ORLANDO, Fla. /eNewsChannels/ -- NEWS: Cancer Diagnostics, Inc. (OTCQB symbol: 'MDIT' / OTC:MDIT), specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, announces change of auditors.
